Finding a prima facie case of infringement, the Delhi High Court recently granted injunction in favour of Dr. Reddy’s-AZIWOK against defendant’s AZIWAKE, noting that the minuscule difference between.
A Division Bench of the Delhi High Court recently held that the government only has power to “monitor” the maximum retail price (MRP) of non-scheduled formulations, and not to fix or revise it. It.
The Delhi High Court has asked the Centre whether demand for COVID-19 drug Tocilizumab, which is in short supply, would be reduced if drug major Roche provides its new antibody cocktail that has been approved for emergency use in India for coronavirus patients. The court also asked the Centre what quantities of the antibody cocktail would be required for the purpose of reducing demand for Tocilizumab. The query was posed to the government by Justice Prathiba M Singh after Roche India, which supplies Tocilizumab in India, told the court it can only endeavour to supply the medicine and cannot assure to meet the market demand for the same, even though patients are willing to pay for it.
Will antibody cocktail of Roche reduce demand for Tocilizumab? HC asks Centre
The court also asked the Centre what quantities of the antibody cocktail would be required for the purpose of reducing demand for Tocilizumab.
Share Via Email
| A+A A-
Health workers and volunteers in personal protective suits wait to receive patients outside a COVID-19 hospital that was set up at a Sikh Gurdwara in New Delhi. (Photo | AP) By PTI
NEW DELHI: The Delhi High Court has asked the Centre whether demand for COVID-19 drug Tocilizumab, which is in short supply, would be reduced if drug major Roche provides its new antibody cocktail that has been approved for emergency use in India for coronavirus patients.
Will antibody cocktail of Roche reduce demand for Tocilizumab: Delhi High Court
SECTIONS
Last Updated: May 14, 2021, 01:02 PM IST
Share
Synopsis
The query was posed to the government by Justice Prathiba M Singh after Roche India, which supplies Tocilizumab in India, told the court it can only endeavour to supply the medicine and cannot assure to meet the market demand for the same, even though patients are willing to pay for it.
Getty Images
The court noted that the global manufacturing figures of the drug have not been filed before it by Roche despite specific directions.
The Delhi High Court has asked the Centre whether demand for COVID-19 drug Tocilizumab, which is in short supply, would be reduced if drug major Roche provides its new antibody cocktail that has been approved for emergency use in India for coronavirus patients. The court also asked the Centre what quantities of the antibody cocktail would be required for the purpose of reducing demand for Tocilizumab.